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Abstract
: Tuberculous meningitis (TBM) has 44% (95%CI 35-52%)Background
in-hospital mortality with standard therapy in Uganda. Rifampicin, the
cornerstone of TB therapy, has 70% oral bioavailability and ~10-20%
cerebrospinal fluid (CSF) penetration.  With current WHO-recommended TB
treatment containing 8-12mg/kg rifampicin, CSF rifampicin exposures
frequently fall below the minimal inhibitory concentration for  .M. tuberculosis
Two Indonesian phase II studies, the first investigating intravenous rifampicin
600mg and the second oral rifampicin ~30mg/kg, found the interventions were
safe and resulted in significantly increased CSF rifampicin exposures and a
reduction in 6-month mortality in the investigational arms. Whether such
improvements can be replicated in an HIV-positive population remains to be
determined.
: We will perform a phase II, open-label randomised controlled trial,Protocol
comparing higher-dose oral and intravenous rifampicin with current standard of
care in a predominantly HIV-positive population. Participants will be allocated to
one of three parallel arms (I:I:I): (i) intravenous rifampicin 20mg/kg for 2-weeks
followed by oral rifampicin 35mg/kg for 6-weeks; (ii) oral rifampicin 35mg/kg for
8-weeks; (iii) standard of care, oral rifampicin 10mg/kg/day for 8-weeks.
Primary endpoints will be: (i) pharmacokinetic parameters in plasma and CSF;
(ii) safety. We will also examine the effect of higher-dose rifampicin on survival
time, neurological outcomes and incidence of immune reconstitution
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 time, neurological outcomes and incidence of immune reconstitution
inflammatory syndrome. We will enrol 60 adults with suspected TBM, from two
hospitals in Uganda, with follow-up to 6 months post-enrolment.
: HIV co-infection affects the bioavailability of rifampicin in the initialDiscussion
days of therapy, risk of drug toxicity and drug interactions, and ultimately
mortality from TBM. Our study aims to demonstrate, in a predominantly
HIV-positive population, the safety and pharmacokinetic superiority of one or
both investigational arms compared to current standard of care. The most
favourable dose may ultimately be taken forward into an adequately powered
phase III trial.
:  (24  April 2018)Trial registration  ISRCTN42218549
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Introduction
Background
Worldwide, 10.4 million people are estimated to have fallen 
ill with Tuberculosis (TB) in 2016, resulting in 1.3 million 
deaths, and an additional 374,000 TB deaths in people living 
with HIV1. The African region carries the greatest burden 
relative to its population; 281 cases for every 100,000 people, 
more than double the global average of 133 per 100,000. Addi-
tionally, of the 1.2 million HIV-infected people who developed 
TB worldwide, 74% were in the African World Health Organisation 
(WHO) region2.
The true incidence of TB meningitis is not known due to lack 
of accurate diagnostics and scarce epidemiological data in 
many TB endemic regions. Central nervous system (CNS) TB 
accounts for ~1% of notified TB cases in Germany and the 
USA, but this proportion is likely to be significantly higher 
in HIV endemic regions where TB frequently manifests as 
disseminated disease3,4. As such, in the wake of the HIV epidemic; 
TB meningitis (TBM) is one of the leading causes of menin-
gitis in both adults and children in Africa5,6. It is estimated there 
is likely to be well over 100,000 cases annually worldwide.
Prognosis of TBM
TBM, the most devastating form of TB, is associated with a 
mortality of 7–28% of HIV-uninfected7, and 29–63% of HIV-
infected patients8,9. The driver of this 2 to 3-fold increased 
risk of death in HIV co-infection has not yet been elucidated. 
Neuro-disability is seen in up to 50% of survivors, regardless 
of their HIV serostatus. TBM cases account for up to 19% of 
all hospitalized HIV-associated TB cases and pose a significant 
challenge to healthcare services and care-givers, often requiring 
prolonged hospital stays and long rehabilitation periods10. 
Delays in seeking medical care, diagnosis, and initiation of 
treatment are contributing factors to the high morbidity and 
mortality, particularly in resource-limited settings.
Clinical TBM management
Early treatment with anti-tuberculous therapy and adjunctive 
corticosteroids is the most effective way of reducing death 
and disability from TBM. However, currently morbidity and 
mortality remains unacceptably high5. Whilst the 4th edition of 
the WHO treatment guidelines suggest substituting ethambutol 
with streptomycin during the intensive phase of treatment this 
has not been widely adopted for a number of reasons, and 
treatment for TBM does not differ from that of pulmonary 
TB, with rifampicin (R), isoniazid (H), pyrazinamide (Z) and 
ethambutol (E) given for two months (intensive phase) followed 
by rifampicin and isoniazid (continuation phase), except that 
continuation phase is prolonged to complete 9–12 months2,11. 
Due to variable TB drug penetration across the blood-brain 
barrier and blood-cerebrospinal fluid (CSF) barrier, optimal 
treatment regimens for pulmonary TB may not be the most 
effective options for TBM. Inadequate CNS drug penetration may 
be an important contributory factor to the high early mortality 
in TBM12. Improved early treatment outcomes may be achieved by 
altering drug selection, drug doses, and routes of administration 
to ensure adequate drug delivery to the site of disease and 
maximal early mycobactericidal activity in the CNS.
Rifampicin in TBM
Rifampicin is the cornerstone drug in the treatment of TBM, 
as evidenced by the fact that those infected with rifampicin- 
resistant Mycobacterium tuberculosis (M.tb) strains have a 
near-universal fatal outcome, even with treatment with second-
line drugs in resource-rich settings5,13,14. Mortality is not nearly 
so high in patients with isoniazid mono-resistant TBM6. 
In addition to male sex and low body weight, which are asso-
ciated with more rapid drug clearance15, malabsorption may 
contribute to reduced systemic drug bioavailability in HIV-infected 
persons16–21. A recent comprehensive meta-analysis of rifampicin 
pharmacokinetics confirmed that during the initial days of 
TB treatment rifampicin total plasma exposure to rifampicin 
is reduced in HIV co-infected adults (AUC 37.2mg.h/L in 
HIV-positive versus 56.7mg.h/L in HIV-negative, p=0.003). 
Interestingly, this association did not persist in steady-state 
(>7 days on therapy, once saturation of first-pass metabo-
lism and the establishment of metabolic autoinduction is well 
established)22. Lower plasma levels of antituberculous agents 
are predictive of poorer outcomes in pulmonary TB23, thus the 
lower plasma levels of rifampicin seen in HIV-positive indi-
viduals in the initial days of TBM therapy may be particularly 
relevant in TB meningitis, which carries a high early mortality. 
Specific factors that potentially play a role in reduced bioavail-
ability include HIV-related enteric infections17,18, HIV-associated 
enteropathy and chronic intestinal immune activation affecting 
regulation of drug transporters. Patients with TBM often 
present while critically ill, are vomiting and frequently receive 
drugs through a nasogastric tube. Such factors may further 
associate with reduced TB drug concentrations, which could 
explain the lower plasma rifampicin concentrations observed 
in patients with TBM compared to those with pulmonary TB 
taking the same dose from the same setting24,25. 
Rifampicin is largely protein bound and thus has limited CSF 
penetration, with reported CSF concentrations often reaching 
10–20% of those in plasma25,26. Suggested target concentra-
tions of rifampicin are >8mcg/ml at the site of disease, but 
CSF rifampicin concentrations seldom exceeded the minimum 
inhibitory concentration (MIC; 0.25mcg/ml) against M. tuber-
culosis at the standard oral adult dose (8–12mg/kg)12. Currently, 
little is known about rifampicin concentrations in brain matter, 
spinal cord or meninges and how plasma levels or inflammation 
affect tissue concentrations.
The evidence for the currently recommended dose of rifampicin 
(10mg/kg/day) in TBM treatment is scant, and this dose falls on 
the steep part of the dose-response curve for sterilising effect27. 
Recent studies by the Pan-African Consortium for the Evalu-
ation of Antituberculous Antibiotics in pulmonary TB have 
shown that rifampicin dosed at 35mg/kg is associated with 
improved early bactericidal activity and 2-fold faster rate of 
sputum conversion (Hazard Ratio 1.99, 95% CI:1.21-3.29) as 
compared to standard therapy. Furthermore, this dose was safe 
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and well tolerated, with a 14% grade 3-5 adverse event incidence 
as compared with 10% with standard 4-drug TB therapy with 
rifampicin dosed at 10mg/kg28.
Ruslami et al. investigated the safety and pharmacokinetic 
(PK) profiles of higher than normal dose intravenous (IV) 
rifampicin as well as oral moxifloxacin in adults with TBM. 
Although not powered to detect a mortality benefit, improved 
survival was observed in patients receiving 600mg IV 
rifampicin (~13mg/kg/day) compared to the oral standard dose 
(~10mg/kg/day). Patients who received IV rifampicin had a 
more rapid resolution of coma (4 versus 5 days), reduced mor-
tality at 8-weeks (24% versus 55%) and 6-months (34% versus 
65%); (adjusted Hazard Ratio=0.42; 95% CI 0.20-0.91, p=0.03) 
compared with those who received oral standard dose rifampicin. 
The change in rifampicin dose and mode of delivery was asso-
ciated with a 3-fold increase in plasma area under the time- 
concentration curve (AUC) and maximum concentration (C
max
) 
and a 3-fold increase in CSF C
max
 from 0.21 to 0.60 mcg/mL.
A second phase II study in Indonesia evaluating increased oral 
doses of 30mg/kg or 20mg/kg versus standard of care (10mg/kg) 
also reported no increase in toxicity in the high dose arms and 
CSF C
max
 was significantly increased (25.5 mg/L [11.9 to 55.5], 
18.1 mg/L [2 to 43.6], 7.2 mg/L [2.2 to 14.1] respectively, 
<0.001). In those with microbiologically confirmed TBM there 
was a trend towards lower 6-month mortality in the 30mg/kg 
arm compared to standard of care (7% versus 36% (HR 0.16 
[0.02 to 1.34], p=0.09)29.
In contrast, a large Vietnamese trial of an intensified TBM treat-
ment containing oral rifampicin 15mg/kg/day versus standard 
of care showed no differential effect on mortality (27.7% versus 
27.9%, hazard ratio 0.94; 95%CI 0.73 to 1.22; p=0.66)30
The conflicting evidence from prior trials evaluating the ben-
efits of higher than standard doses of rifampicin for TBM 
creates a situation of equipoise that can only be answered with 
an adequately powered phase III trial examining a rifampicin 
dose with proven pharmacokinetic-pharmacodynamic superiority 
to the standard of care. This phase II study aims to demonstrate 
pharmacokinetic superiority of one or both of the investiga-
tional arms so that the most favourable dose may ultimately be 
taken forward into a phase III study. Additionally, it is important 
to generate PK and safety data from HIV-positive African 
adults, as HIV co-infection can have a significant impact on 
TBM outcomes, pharmacokinetics and drug toxicity.
Protocol
This is version 1.2.1, 19th February 2018.
Hypotheses
Our primary hypothesis is that intravenous rifampicin (20mg/kg) 
and high dose oral rifampicin (35mg/kg) will result in signifi-
cantly increased plasma and CSF exposure during the critical 
early days of TBM treatment as compared to standard control 
(10mg/kg oral rifampicin).
Our secondary hypotheses are that high dose rifampicin will 
lead to improved early mycobacterial clearance from the CNS, 
reduced inflammatory response, and thereby will result in more 
rapid resolution of coma, improved long-term functional status, 
reduced TBM immune reconstitution inflammatory syndrome 
(IRIS) incidence and lower mortality.
Main study objectives
Primary objective. Our primary objective is to determine whether 
higher-dose rifampicin, delivered either orally at 35mg/kg/day 
or intravenously at 20 mg/kg/day for 2-weeks (followed by 
orally at 35 mg/kg/day for 6-weeks) is safe and provides expo-
sure profiles that are favourable compared to the 10 mg/kg 
standard dose oral rifampicin.
Secondary objectives. Our secondary objectives are to observe 
whether greater rifampicin exposure in CSF is associated with 
any clinical benefit including more rapid resolution of coma, 
improved long-term functional status, reduced TBM-IRIS 
incidence and lower mortality.
Ancillary studies
Two ancillary studies will be conducted within the RifT trial, the 
second of which will only take place at Mulago Hospital.
Evaluation of the diagnostic accuracy of Xpert MTB/Rif 
Ultra (Ultra) in TBM. Our hypothesis is that CSF Ultra is 
significantly more sensitive than CSF Xpert MTB/Rif or culture 
in the diagnosis of TBM.
Descriptive study of brain tissue rifampicin concentrations on 
autopsy specimens. Our hypothesis is that brain tissue con-
centrations will correlate with plasma and CSF concentration 
and will be significantly higher in the investigational arms.
Design and setting
RifT is a three arm, parallel group, phase II open label randomised 
controlled trial (see Figure 1), evaluating three rifampicin regi-
mens over an 8-week intervention period, as follows:
A.    Intravenous 20mg/kg/day rifampicin for 2-weeks 
(followed by oral rifampicin 35mg/kg/day for 6-weeks)
B.    Oral 35mg/kg/day rifampicin for 8-weeks
C.    Standard of care oral rifampicin (~10mg/kg/day) for 
8-weeks
All participants will receive a standard backbone of oral TB 
treatment (consisting of isoniazid ~5mg/kg/day, pyrazinamide 
~25mg/kg/day, ethambutol ~20mg/kg/day) and daily IV dex-
amethasone (0.4mg/kg/day) for 1 week then weaned over a 
6–8 week period, as per WHO guidelines.
The trial will be set in two hospitals in Uganda: Mulago National 
Referral Hospital and Mbarara Regional Referral Hospital. 
The study population will be adults (≥18 years of age) with 
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a diagnosis of TBM and treatment for TBM planned by the 
attending physician.
Endpoints
Primary end points
1. Pharmacokinetic parameters
Plasma and CSF rifampicin area under the curve (AUC0-24h), and 
maximum concentration (C
max
)
2. Adverse events
We will use a composite safety endpoint for the 8-week inter-
vention period that includes clinical grade 3-5 adverse events 
(AEs) (as classified by Division of AIDS (DAIDS) Toxicity 
Scale) or all serious adverse events (SAEs), drug-induced 
liver injury (DILI), grade 3-5 defined by alanine transaminase 
(ALT) >5x upper limit of normal (ULN), or discontinuation of 
rifampicin for >5 consecutive days in the first 8 weeks for any 
cause.
Secondary endpoints
1. Mortality
Mortality at 8- and 24-weeks post randomisation will be 
compared between study arms.
2. Time to normalization of conscious level
We will determine days from randomisation until observation 
of a GCS of 15 which is achieved for ≥2 consecutive days.
3. Functional status
The modified Rankin scale at 8 and 24 weeks will be used in 
determining functional outcomes.
4. TB immune reconstitution inflammatory syndrome
TB-IRIS will be diagnosed according to published case 
definitions31. TB-IRIS will be determined independently by 2 trial 
clinicians blinded to treatment allocation.
Inclusion and exclusion criteria
Inclusion criteria. Participants to be included in the study are 
consecutive patients ≥18 years with clinically suspected TBM 
based on meningitis symptoms, clinical signs of meningism and 
anti-tuberculous chemotherapy planned by the attending physi-
cian. In addition, they must have either a bedside CSF glucose to 
plasma ratio <50%, or absolute CSF glucose <40mg/dl or 
2.2mmol/l or a positive CSF acid fast bacilli (AFB) smear or 
positive Xpert MTB/Rif or Ultra. Written informed consent 
must be given by either by the participant or by surrogate if the 
participant has altered mental state.
Figure 1. Study flow chart.
Meningitis symptoms n=800
Diagnostic sub-study on Ultra Diagnostic lumbar puncture for TBM panel n=240
Suspected or confirmed TBM enrolled to RIFT study n=60
Likely cryptococcal meningitis n=560
If CSF crAg is
negative can
undergo testing
for TBM
IV Rifampicin 20mg/kg/day
standard of care HZE
n=20
Oral Rifampicin 35mg/kg/day
standard of care HZE
n=20
Standard of care RHZE
n=20
Day 2 (+/-1): Plasma PK: 0,2,4,8 hours post dose. CSF PK sample
Day 12 (+/-2): single plasma and CSF PK sample
Day 14 switch IV Rifto PO 35mg/kg/day
Daily clinical review. Timing of hospital discharge as clinically indicated.
Week 4 (+/-1) outpatient visit: medication and clinical review
Week 24 (+/-2): detailed neurocognitive assessment, med review, clinical review
Study termination
Week 8 (+/-1): detailed neurocognitive assessment, clinical review
Medication review: begin standard dose continuation phase of TB treatment
HIV: adherence counseling session, initiate/switch ART
4 weekly follow-up in HIV clinic after initiating ART
In event of IRIS for study physician review, LP, labs, and treatment
Cryptococcal antigen (blood)
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Exclusion criteria. Patients with jaundice or known liver cir-
rhosis will not be eligible to enrol. Additionally, those who have 
received more than 3 doses of TB treatment within the previous 
3 days, or have discontinued TB treatment in the prior 14 days, or 
those with known allergy to rifamycins, isoniazid, pyrazinamide, 
ethambutol or study drug excipients are not eligible. Those with 
known current/previous rifampicin drug-resistant M. tuberculosis 
infection or those with concurrent cryptococcal meningi-
tis or those known to be currently taking any drug that has a 
clinically relevant interaction with rifampicin or other first-line 
TB drugs, including ritonavir, atazanavir or darunavir will not be 
eligible. Individuals who cannot or are unlikely to attend regular 
clinic visits or are pregnant or breastfeeding or where we lack 
consent from participant or family members are not eligible. 
Those with known porphyria or known chronic renal failure with 
eGFR <10ml/min are not eligible.
Randomisation and treatment allocation
Adults who have given consent for, and undergone, a diagnostic 
screening lumbar puncture and are eligible for enrolment will 
then be approached for enrolment consent after which they 
will be randomised. Randomisation will occur at study entry 
and must occur prior to the 4th dose of TB treatment. Partici-
pants will be randomised by a computer generated permutated 
block randomization algorithm of different sized blocks with a 
1:1:1 randomization ratio into the three arms described above.
Randomisation will be stratified by:
1.   Clinical site
2.    British Medical Research Council (BMRC) TBM disease 
grade I or II/III at time of consent
All randomised participants will initiate their allocated study 
TB treatment within 24 hours of randomisation, and preferably 
the same day. As TBM is a medical emergency, initiation 
of standard of care TB treatment will not be delayed whilst 
waiting for randomisation.
Treatment discontinuation. Due to the urgent need to begin 
TBM therapy to reduce mortality, enrolment will not be delayed 
whilst waiting for enrolment blood test results and partici-
pants will be replaced a posteriori if baseline ALT>3x ULN. 
As infection with a rifampicin resistant TB strain is an exclu-
sion criterion, all patients in whom rifampicin resistant TB is 
identified after randomisation may have their treatment altered 
as per physician judgement. Once randomised, analysis is 
by modified intent-to-treat (ITT).
Interventions
Diagnostic lumbar puncture. At the time of screening, after 
informed consent has been received, a diagnostic lumbar 
puncture will be performed with a ~10ml CSF sample collected. 
The sample with then be tested with an enhanced TB diagnostic 
panel including Xpert MTB/Rif, Ultra, MGIT culture, Biofire 
meningoencephalitis multiplex polymerase chain reaction and 
next generation sequencing.
Antituberculous therapy
Intravenous rifampicin arm (R20IV)
For the first 14 days study drug will be administered as intrave-
nous rifampicin 20mg/kg once daily. Study medications will be 
dispensed during hospitalization to ward staff who will adminis-
ter the drugs to the participants under directly observed therapy. 
Rifampicin 600mg will be reconstituted with 10 ml of sterile 
water for a dilution of 60 mg per ml of reconstituted solution. The 
weight-specific volume of rifampicin solution will be drawn up 
(Table 1) then further diluted in 500 ml 5% Dextrose solution. 
The solution will be administered as a continuous infusion 
via a peripheral venous catheter over 2 hours. Thereafter the 
line will be flushed with 5 ml 0.9% normal saline after which 
the cannula will be capped. Other antituberculous drugs 
(isoniazid, pyrazinamide and ethambutol) will be given orally by 
weight (Table 2) as intact tablets unless they are unable to 
swallow voluntarily, e.g. in participants with a depressed level 
of consciousness, in which case tablets will be crushed and 
given via nasogastric tube.
After 14 days of intravenous rifampicin the participant will 
be switched to high dose oral rifampicin (35mg/kg) for the 
remaining 6 weeks of the intervention period administered as 
per the participants in the high dose oral rifampicin arm.
High dose oral rifampicin arm (R35PO) Oral rifampicin 
at 25mg/kg for 8 weeks, in addition to standard fixed dose 
combination quadruple antituberculous tablets containing 
~10mg/kg of rifampicin, will be administered for the first 
8 weeks. Fixed-dose combination tablets according to weight 
bands as presented (Table 3) will be dispensed with addi-
tional 300mg oral rifampicin tablets to make the rifampicin 
dose up to ~35mg/kg/day. All study drugs will be taken orally 
during this period (either as intact tablets or via nasogastric 
tube). Study drugs will be administered under directly observed 
therapy by nursing staff whilst the participant remains in 
hospital. After discharge study drugs will be dispensed to 
participants at the week 4 visit. Fixed dose combination antitu-
berculous therapy will be prescribed through routine care 
pathways initially via the hospital and subsequently via linked 
TB clinics according to National Guidelines. Participants will 
be weighed at each visit and TB drug dose will be adjusted 
as necessary. At the end of the intervention period (week 8) 
the participant begins standard of care continuation phase TB 
treatment (Table 4).
Control arm, standard of care arm (R10PO) The control 
arm will receive standard of care TB treatment: Oral rifampicin 
~10 mg/kg, isoniazid ~5 mg/kg, pyrazinamide ~25 mg/kg, 
ethambutol ~20 mg/kg in fixed-dose combination tablets 
according to weight bands for 8 weeks (Table 4). Participants 
will receive intact tablets or via nasogastric tube. Fixed dose 
combination antituberculous therapy will be prescribed through 
routine care pathways initially via the hospital and subsequently 
via at TB clinics according to National Guidelines.
Pharmacokinetic sampling. Intensive plasma PK sampling 
will take place on day 2(+/-1) at hours 0, 2, 4 and 8 post dose 
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Table 1. Intravenous administration of rifampicin by weight for day 
0–14 in the intravenous rifampicin arm (arm R20IV).
Weight (Kg) Rifampicin dose (mg)
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28.5 – 31.49 600 10 1.0
31.5 – 34.49 660 11 1.1
34.5 – 37.49 720 12 1.2
37.5 – 40.49 780 13 1.3
40.5 – 43.49 840 14 1.4
43.5 – 46.49 900 15 1.5
46.5 – 49.49 960 16 1.6
49.5 – 52.49 1020 17 1.7
52.5 – 55.49 1080 18 1.8
55.5 – 58.49 1140 19 1.9
58.5 – 61.49 1200 20 2.0
61.5 – 64.49 1260 21 2.1
64.5 – 67.49 1320 22 2.2
67.5 – 70.49 1380 23 2.3
70.5 – 73.49 1440 24 2.4
73.5 – 76.49 1500 25 2.5
76.5 – 79.49 1560 26 2.6
79.5 – 82.49 1620 27 2.7
82.5 – 85.49 1680 28 2.8
85.5 – 88.49 1740 29 2.9
88.5 – 91.49 1800 30 3.0
Table 2. Daily number of tablets of isoniazin, pyrazinamide 
and ethambutol by weight during the first 14 days for the 
intravenous rifampicin study arm (arm R20IV).
Baseline 
weight (kg)
ISONIAZID 
100 mg*
PYRAZANAMIDE 
500 mg*
ETHAMBUTOL 
400 mg
≤30–33 1.5 1.5 1
34 1.5 1.5 2
35–44 2 2 2
45–54 2.5 2.5 2
55 3 3 2
56–64 3 3 3
65 3 3.5 3
≥66 3.5 3.5 3
as well as a single CSF sample. Where possible a single plasma 
and CSF sample will be collected on day 14 (+/- 2 days).
Blood test monitoring. Routine blood monitoring will take 
place on days 1, 3, 7 and 14, week 4 and week 8 to monitor for 
any rifampicin-related toxicity (Table 5 and Table 6).
Neurocognitive assessment. Where possible a detailed neurocogni-
tive assessment will take place on week 8 and week 24.
Antiretroviral therapy. HIV-positive participants who are ART 
naïve or who have defaulted ART will initiate ART after com-
pletion of the intensive phase of TB treatment (at week 8) 
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Table 3. Daily administration of oral rifampicin during the first 8 weeks in 
the high dose oral rifampicin arm (R35PO) and week 2–8 in arm R20IV.
Weight Number of RHZE tabs 
(150/75/400/275 mg)
Additional rifampicin 
300mg tablets
Total rifampicin 
dose (mg)
30–37 kg 2 tabs 3 tabs 1200
38–54 kg 3 tabs 4 tabs 1650
55–70 kg 4 tabs 5 tabs 2100
≥ 71 kg 5 tabs 6 tabs 2550
Table 4. Daily number of fixed dose tablet in the control arm (arm R10PO) 
during week 0–8 and for all arms during the continuation phase of treatment.
Weight Intensive Phase (week 0–8) Continuation Phase 
(month 3–12)
RHZE fixed dose combination daily 
(150/75/400/275 mg)3
RH (150/75)3 RH (300/150)3
30–37 kg 2 tabs 2 tabs
38–54 kg 3 tabs 3 tabs
55–70 kg 4 tabs 2 tabs
≥ 71 kg 5 tabs 2 tabs
in accordance with WHO and Ugandan guidelines. An efavirenz 
-based regimen or dose-adjusted (twice daily) dolutegravir- 
based regimen would be used in accordance with Ugandan 
HIV treatment guidelines (currently under revision)32. Partici-
pants who were enrolled on a failing efavirenz-based regimen 
will be switched at week 8 to a dose-adjusted dolutegravir-based 
regimen. Current protease inhibitor or nevirapine-based ART 
is an exclusion criteria so we do not anticipate having partici-
pants on these agents. All participants will be registered at the 
Infectious Diseases Institute HIV clinic or the Mbarara Hospital 
HIV clinic such that their HIV care lies within the national HIV 
service framework.
Adverse events and safety reporting
The principles of ICH GCP require that both investigators and 
sponsors follow specific procedures when notifying adverse 
events or reactions in clinical trials. The definitions of the EU 
Directive 2001/20/EC Article 2 based on the principles of ICH 
GCP apply to this trial protocol. All adverse events will be 
assessed for seriousness, causality and expectedness. Causality 
in relation to study drug (rifampicin) is assessed as unrelated, 
unlikely, possible, probable or definite based on temporal 
relationship and clinical judgement. If the event is serious and 
unrelated or unlikely to be related it is classified as an SAE. If 
the event is possibly, probably or definitely related it is clas-
sified as a Serious Adverse Reaction (SAR). Expectedness 
of the adverse reaction is assessed using the summary of 
product characteristics (SPC) at the time of the event. An 
unexpected adverse reaction is one not previously reported in the 
SPC, or one that is more frequent or more severe than previously 
reported. If a SAR is assessed as being unexpected it becomes 
a suspected unexpected serious adverse reaction (SUSAR). 
Intensity will be graded using the DAIDS toxicity scale.
The Trial Management Group at the Infectious Diseases Insti-
tute (IDI) must be notified of all grade 3-5 AEs, SAEs and 
SARs within 24 hours, thereafter they are responsible for 
reporting SAEs, SUSARs to the Sponsor, regulatory authorities 
and ethics committees in accordance with local regulatory and 
institutional guidelines.
Interim analyses. Interim analysis of safety will occur after 
24 participants (8 per arm) have completed the week 8 visit. 
The committee can modify the frequency of interim analysis 
and early termination could occur if the data safety committee 
decides there is an unacceptable level of toxicity in any of the 
investigational arms.
Data collection
Baseline and subsequent assessment. Participants will be fol-
lowed as in-patients for the first 14 days and then approxi-
mately 4 weekly as outpatients until week 24, see Table 5 and 
Table 6. If a trial participant dies during the in-patient period 
additional consent will be sought from family members for a 
post-mortem examination to explore cause of death and levels 
of rifampicin in brain tissue. Recruitment will continue for 
12–18 months with an additional 6 months follow-up period. 
The trial will be considered closed when the last participant 
has completed 24 weeks in the study, all SAEs resolved and all 
follow-up and laboratory reports have been received.
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Table 5. In-patient schedule of events.
Study visit Screening Enrolment D1 Day 2 Day 3 Day 7 Day 10 Day 14 Further 
Hospitalization
Visit window (days) ±1 ±1 ±1 ±1 ±2
Screening Consent X
Assess eligibility criteria X
Informed enrolment consent X
Clinical history and examination
Past medical history (X)
Medication review (X) X X X X X X X
Document HIV status (X)
Current symptoms (X) X X X X X X X
Examination (X) X X X X X X X
GCS score (X) X X X X X X X
BMRC disease grade X X X X X X X
Adverse events assessmentb X X X X X X X
Investigations
HIV-test (if not known positive) (X)
Cryptococcal antigen (X)
Sodium/Potassium Xi Xi X X X
Glucose (bedside) (X)
Creatinineh Xi Xi X X X
Hepatic panela Xi Xi X X X X
Blood Count (including differential) Xi Xi X X
CD4 count if HIV-positive Xi Xi
Pregnancy test Women
CSF sample (aim >10ml, as per SOPc) (X) Xd as clinically indicated 
(storage of remaining 
specimen)
X 
(Paired 
plasma)
X  
(as clinically 
indicated)
Plasma PK sampling 0, 2, 4, 8 hrs X
Sparse plasma PK (one sample) X
Chest radiograph (+/-)
CT headf +/- +/-
Abdominal Ultrasound Scan X
Urine sampleg (X)
Blood/DNA/RNA storage with consent with consent
Approx. volume blood (mL) 0 20 20 3 7 0 7 7
()= part of routine medical care
a
 Hepatic panel = alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin. Hepatitis BsAg, Hepatitis C Ab and INR will be 
added if baseline ALT is elevated. In the event of DILI hepatic panel will be performed more regularly.
b
 Adverse events will be recorded according to DAIDS toxicity scale
c
 SOP = standard operating procedure detailing exact processing and testing algorithm of CSF
d
 CSF PK will be timing randomised to early (2–4hrs) or medium (4–6hrs) or late interval (6–8hrs) post dose.
f
 Contrast enhanced CT head is indicated if there is focal neurology at baseline or during enrolment period
g Urine sample may be collected for testing with LAM (lipoarobinmannan) or urine Xpert MTB/Rif Ultra as part of TB work-up
h Additional renal monitoring will be undertaken in those with abnormal baseline creatinine
i Baseline bloods must occur at either screening or enrolment visit. It is likely these visits will be on the same day. If baseline bloods were 
done at screening and enrolment occurs >48 hours later baseline blood tests will be repeated.
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Data handling and data management. Source documents are 
made up of detailed case report forms (CRFs), laboratory results, 
radiology results and other relevant documents. Data entry 
will occur via the DataFax system, whereby the paper-based 
case record forms are scanned, emailed to a server, and data 
entered by intelligent character recognition. After an initial auto-
mated error-checking, secondary review for accuracy is then 
performed by the DataFax team at the Infectious Diseases 
Institute, Uganda. The DataFax system allows for automated 
data queries to alert for any missing data on an ongoing basis. 
Second, this also allows for permanent archiving and potential 
remote review by oversight bodies. Study forms will be har-
monized between all study sites enabling multi-site data 
management. The investigator will retain study essential source 
documents for 20-years after the completion of the study, as 
per Ugandan guidelines. Digital images of the source documents 
will be retained for an indefinite period.
Quality control and assurance. Site monitoring is conducted 
to ensure that the human subject protection, study procedures, 
laboratory, study intervention administration, and data collection 
processes are of high quality and meet the sponsor, ICH E6 
and regulatory guidelines. The study may be subject to audit 
by the London School of Hygiene & Tropical Medicine under 
their remit as Sponsor, as well as other regulatory bodies to 
ensure adherence to Good Clinical Practice.
Statistical considerations
Sample size. Approximately 800 adults presenting with symp-
toms of meningitis will be assessed, of which it is anticipated 
two-thirds will have cryptococcal meningitis. The circa 240 
patients with negative CSF cryptococcal antigen (crAg) will 
undergo a comprehensive TBM diagnostic panel (Xpert MTB/Rif, 
Xpert Ultra, mycobacterial growth indicator tube (MGIT) culture, 
and/or next generation sequencing) from which we anticipate 
Table 6. Out-patient schedule of events.
Study visit Week 4 Week 8 Week 12 Week 18 Week 24 Sick Visit
Visit window (weeks) ±1 ±1 ±1 ±2 ±2 As needed
Dispensing of study drug X standard fixed dose therapy til 12 months as 
per local guidelines
Interim history X X X
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X X
Adverse events assessment X X X X X
Medication review X X X X X
Examination X X X X X
Modified Rankin score X X
Detailed neurocognitive follow-up X X
Center for Epidemiological Studies 
of Depression Scale (CES-D)
X X
Sodium, potassium X (if clinically 
indicated)
Creatinine X (if clinically 
indicated)
Hepatic Panela X X X (if clinically 
indicated)
FBC, differentialb X (if clinically 
indicated)
Storage bloodsc X X (IRIS event 
only)
CSF with storage X (if clinically 
indicated)
ART counsellingd X X
Commence/switch ARTd X
Total volume of blood (ml) 20 20
aHepatic panel = ALT, ALP, bilirubin +/- INR
bFBC; full/complete blood count
cBlood will be collected and stored for research if storage consent has been received, refer to site SOP.
dHIV-infected patients not receiving effective ART, ART counselling to be performed by qualified counsellors 
as per standard clinic procedures. Physician discretion allowed for timing of ART initiation.
Page 10 of 20
Wellcome Open Research 2018, 3:83 Last updated: 06 SEP 2018
60 people with suspected or confirmed TBM will be recruited 
into the randomised trial.
The sample size is determined following the assumption that PK 
parameters are normally distributed on the log scale. Estimated 
rifampicin log-transformed C
max
 standard deviation is taken 
from Ruslami et al.1 The global study significance level (alpha) 
will be 10%, which is appropriate for phase II studies. Using 
the Bonferonni correction for multiple testing, each individual 
comparison will be made with alpha of 5%. Group sample sizes 
of n=15 achieve 90% power to reject the null hypothesis of equal 
means when the log-transformed population mean difference 
is 0.54mg/L with standard deviation of ±0.36mg/L in the 
control group and ±0.48mg/L (33% higher) in the experimen-
tal group, with a significance level of 0.05 using a two-sided, 
two sample unequal variance t-test. If the standard deviation 
differs from our estimate, the overall detectable effect size at 90% 
power will be 1.5 times the standard deviation, and 1.27 times the 
standard deviation at 80% power. We will not formally compare 
equivalence of the two investigational arms as this would require 
a larger sample size. Comparison of the two investigational 
arms will be primarily descriptive.
This phase II study would be underpowered to detect a survival 
benefit unless the effect size is large. A one-sided log rank test 
with 20 subjects per arm provides 80% power at 0.05 signifi-
cance to detect a hazard ratio of 0.285 when 40% of controls 
survive 8-weeks. This assumes no more than 1 person drops 
out or is lost to follow-up per arm. The prior lost to follow up 
rate has been <1% in recent Ugandan meningitis trials.
Statistical methods. After data cleaning, analysis will proceed 
according to the pre-specified analysis plan using Stata version 
13. The trial will be reported in accordance with CONSORT 
guidelines and primary analyses will be conducted by the 
participant’s originally assigned group (ITT). Analyses will be 
conducted on individuals from both study sites together and all 
analyses will be adjusted for site, BMRC grade and any baseline 
variables associated with missingness of the analysis outcome.
Primary analysis
Pharmacokinetic analysis
The following pharmacokinetic parameters will be calculated 
using standard two-stage approach involving calculation of phar-
macokinetic parameters in those patients in whom a full PK 
curve was recorded:
1.    C
max
 - the peak concentration of the drug after administra-
tion
2.    T
max
 - the time to reach C
max
3.    AUC0-24 - area under the time concentration curve from 
hour 0 to hour 24
4.    Time > MIC is the duration of time where the drug 
concentration level is greater than the minimal inhibi-
tory concentration for the M. tuberculosis isolate (either 
the individual or the median MIC of the study population)
Safety analysis
The number and proportion of individuals who reported any 
kind of clinical grade 3-5 AE during the study period will be 
presented by intervention arm. Data for safety will be analysed 
in accordance with the ITT principle. The main analysis will 
be a composite safety endpoint over the 8-week intervention 
period:
•    AEs, clinical Grade 3-5 as classified by DAIDS Toxicity 
Scale
•    All SAEs
•    DILI, grade 3-5 (ALT >3x ULN with symptoms or 
5x ULN without symptoms)
•    Discontinuation of rifampicin for >5 days in the first 
8 weeks for any cause
Time to experiencing an adverse event will be compared 
between treatment arms using cumulative incidence functions 
and a Cox proportional hazards regression model adjusted 
for site and BMRC TBM grade. Death will be considered a 
competing risk. The individual subgroups of AEs that make up 
the composite endpoint will be summarised. A secondary analysis 
of rifampicin-related toxicity (probable or definitely related, 
as assigned on the adverse events case record form) will be 
presented by intervention arm.
Clinical outcomes
Survival at 8 and 24 weeks will be calculated using the risk 
difference, from a generalised linear regression model adjusted 
for site and BMRC TBM grade. Kaplan-Meier curves will also 
be used to compare time to death between treatment arms, with 
censoring and loss to follow-up handled as previously described. 
Cox proportion hazards regression will be used to assess the 
effects of rifampicin dose, plasma/CSF rifampicin concentration, 
HIV, MRC severity grade and baseline GCS on survival.
When calculating time to normalization of GCS continuous- 
valued secondary endpoints will be compared with general linear 
models or Wilcoxon rank-sum tests as appropriate. Death can be 
considered a competing risk. χ2 test will be used for comparison 
of proportions of patients with TBM-IRIS by intervention arm.
Secondary analysis. We will explore the relationship between 
rifampicin exposures and clinical outcomes using a population 
pharmacokinetic-pharmacodynamic model. We will consider 
C
max
 and AUC0-24h as the exposure variables. Survival, pro-
portion with normalisation of conscious level and functional 
status (as determined by modified Rankin score) are the response 
variables.
Planned subgroup analyses. Specified high-risk subgroups are 
of interest because of potential different responses to intrave-
nous rifampicin from both an efficacy and safety perspective, 
and the clinical utility in future physician decision-making. 
With standard therapy, worse clinical outcome is associated 
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with altered mental status, high organism burden. Subgroups of 
interest include:
1.   TBM Diagnostic category (Definite, Probable, Possible)33
2.    British Medical Research Council (BMRC) TBM disease 
severity7
3.   CSF inflammation (CSF white blood cells) by tertiles
4.   CD4 at study entry
5.   ART status at study entry
Analysis of ancillary studies. The results of ancillary studies 
will be reported separately from the main trial.
Findings of the diagnostic sub-study will be reported in line 
with the Standards for the Reporting of Diagnostic Accuracy 
studies (STARD) guidelines. Sensitivity and specificity will be 
calculated against a composite reference standard (any positive 
CSF test for M. tuberculosis) and against the published uni-
form case definition of ‘probable’ or ‘definite’ TBM33. A latent 
class analysis will also be performed.
The studies on brain tissue concentration at autopsy will be 
primarily descriptive.
Ethical considerations
Confidentiality. Participants will be identified only by means 
of a coded identification number specific to each participant. 
All participant-related information (including CRFs, laboratory 
results, radiology reports etc.) will be kept strictly confi-
dential. All records will be kept in a secure, locked location 
and only research staff will have access to the records. With 
consent, information relevant for the future HIV care will be 
shared with relevant HIV clinic for continuity of care and patient 
safety.
All computerized databases will identify participants by numeric 
codes only, and will be password-protected. Upon request, 
participant records will be made available to the study sponsor, 
monitors, applicable regulatory entities, including the Uganda 
National Council of Science and Technology, Uganda National 
Drug Authority, Mulago Institutional Review Board, or London 
School of Hygiene and Tropical Medicine.
Consent. An estimated >80% of the study population will have 
altered mental status at initial hospital presentation. Those 
presenting with meningitis and altered mental status are at the 
greatest risk of death, and enhanced TBM therapy may have 
the greatest benefit for them. This hypothesis deserves testing 
via inclusion into the clinical trial. Secondly, as most persons 
with TBM present with altered mental status, in order to make 
results generalizable to all TBM patients, we wish to offer enrol-
ment to all persons. Subjects unable to give informed consent 
due to altered mental status may have surrogate consent provided 
by proxy from their caregiver/next of kin.
For subjects enrolled by surrogate consent, if and when the 
participant regains the physical and mental capacity to give 
consent, information will be provided to them and written 
informed consent will be sought for continuation in the trial. If a 
patient or representative declines to give consent for continuation 
at this stage, his/her wishes will be respected.
A person who speaks and understands the language of the 
informed consent document, but does not read and write, can be 
enrolled in a study by “making their mark” or via a thumbprint 
on the informed consent document. In this event, an impartial, 
literate third party must witness the entire consent process 
and sign the informed consent document. The witness’s name, 
signature, and relationship must be recorded on the informed 
consent document. A member of the study team is not an 
impartial third party.
Supplementary File 1 contains the participant information sheet 
and consent form.
Sample use and storage. Additional consent will be sought 
for the long-term storage of samples (including blood, spinal 
fluid, DNA/RNA) for use in future research. In this case, sam-
ples will be stored for the purposes of future research, unless 
the subject asks for them to be destroyed. Alternatively, subjects 
may give limited consent to the collection and testing of 
samples for the purposes of this research only, after which the 
samples will be destroyed.
Withdrawals. Subjects may withdraw from the study at any 
time by withdrawing subject consent, and will be eligible to 
continue to receive TB treatment from a primary TB clinic of 
their choice. Subjects enrolled in the study but choosing to 
leave the hospital early against medical advice will continue to 
participate in the study if they wish. Additional phone calls by 
study personnel will encourage the subject to seek follow up 
TB care and to re-join the trial per the on-going schedule of 
events. Assessment of vital status will continue via telephone 
calls at a minimum, unless consent is completely withdrawn. 
Participants will be asked if they would like their accrued data 
to be destroyed.
Ethical approval. The investigators have obtained approval 
from the Research Ethics Committees of the London School 
of Hygiene and Tropical Medicine (14388), as well as the 
Mulago Hospital Institutional Review Board (MHREC1260), 
the Uganda National Council of Science and Technology, the 
Ugandan National Drug Authority and Mbarara Hospital.
Any further amendments will be submitted and approved by 
each ethics committee.
Trial committees
The trial sponsor is London School of Hygiene and Tropical 
Medicine (LSHTM; Keppel Street, London, WC1E 7HT, UK; 
Tel: 0207 6368636). The trial management group (TMG) will 
oversee day to day management of the trial and is formed of the 
principal investigators (PI), site PI in Mbarara, a neurologist and 
a statistical advisor. The TMG will meet weekly. The trial steer-
ing committee (TSC) has members of the TMG and independent 
members (Professor Guy Thwaites (Chair), Professor Alison 
Elliott, Professor Reinout van Crevel, Dr Joe Jarvis, Dr Frank 
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Mugabe (Head of National TB and Leprosy Programme), 
a patient representative). The TSC provides supervision for 
the trial and advice through the independent Chair. The data 
safety committee (DSC) (Professor Robert Wilkinson (Chair), 
Dr William Worodria, Dr Mindy Clarke, Dr Agnes Kiragga 
(independent statistician), Dr Christine Sekaggya-Wiltshire) will 
advise the TSC regarding continuation, modification or premature 
closure of the trial. The DMC is independent from the Sponsor.
Publication policy
We will share results though presentations at scientific confer-
ences and in peer-reviewed open-access journals. De-identified 
individual patient data will be stored on LSHTM secure data 
repository (LSHTM Data Compass) for patients who have given 
consent to data sharing at the time of enrolment.
Discussion
Tuberculous meningitis is highly fatal despite current WHO 
recommended therapy, particularly in HIV-positive people, who 
are 2–3 times more likely to die than their HIV-negative coun-
terparts. Recent evidence from Indonesian phase II studies 
suggests that significantly higher dose IV or oral rifampicin 
enhances CNS penetration and may reduce mortality. However, 
there is currently no available pharmacokinetic data on high-
dose rifampicin for TBM in an HIV-positive African population. 
Furthermore, intravenous rifampicin is not widely available so 
finding a bioequivalent oral dose, that reaches target levels in the 
CNS, is a priority.
In this phase II study we anticipate the sample size will not be 
sufficient to detect small differences in mortality between the 
treatment arms. However, the pharmacokinetic and pharmaco-
dynamic data will be used to define optimal rifampicin dose, 
and route of administration in an HIV-positive population, and 
this will be taken forward into a larger phase III randomised 
controlled trial, if safe and tolerable.
Data availability
No data are associated with this article.
Competing interests
Sanofi are donating IV and oral Rifidin for the purposes of the 
trial. Sanofi were not responsible for protocol design and will 
be independent from the analysis and reporting of the trial.
Grant information
The trial is funded through a Wellcome Trust Clinical PhD 
Fellowship [210772], sponsored by London School of Hygiene 
and Tropical Medicine, UK and hosted by the Infectious Diseases 
Institute, Uganda.
The funders have had no role in the trial design, and will not be 
involved in the collection, analysis, and interpretation of data; in 
the writing of the report; or in the decision to submit the paper 
for publication.
We acknowledge the support offered by the individual sites 
and staff at Mulago and Mbarara Hospitals; the Trial Steering 
Committee & Data Safety Committee for monitoring the 
trial.
Acknowledgements
FVC is an honorary fellow of the Makerere University – Uganda 
Virus Research Institute Centre of Excellence for Infection 
and Immunity Research and Training (MUII-plus). MUII-plus 
is supported through the DELTAS Africa Initiative (Grant no. 
107743). The DELTAS Africa Initiative is an independent 
funding scheme of the African Academy of Sciences (AAS), Alli-
ance for Accelerating Excellence in Science in Africa (AESA), 
and supported by the New Partnership for Africa’s Development 
Planning and Coordinating Agency (NEPAD Agency) with 
funding from the Wellcome Trust (Grant no. 107743) and the 
UK Government. Dr Brigitte Demers (Sanofi Pasteur) has been 
instrumental is facilitating the donation of Rifidin. We acknowl-
edge the institutional support of Dr Andrew Kambugu and the 
research office and the Infectious Diseases Institute as well 
as the clinical trials office at the London School of Hygiene 
and Tropical Medicine.
Supplementary material
Supplementary File 1: Participant information sheet and consent form.
Click here to access the data.
References
1. Organisation WH: Global Tuberculosis Report 2017. Geneva: World Health 
Organisation, 2017.  
Reference Source
2. Organisation WH: Global Tuberculosis Report 2016. Geneva, Switzerland: World 
Health Organisation, 2016.  
Reference Source
3. Ducomble T, Tolksdorf K, Karagiannis I, et al.: The burden of extrapulmonary 
and meningitis tuberculosis: an investigation of national surveillance data, 
Germany, 2002 to 2009. Euro Surveill. 2013; 18(12): pii: 20436.  
PubMed Abstract | Publisher Full Text
4. Control CfD: Reported Tuberculosis in the United States, 2016. 2017.  
Reference Source
Page 13 of 20
Wellcome Open Research 2018, 3:83 Last updated: 06 SEP 2018
5. Marais S, Pepper DJ, Schutz C, et al.: Presentation and outcome of tuberculous 
meningitis in a high HIV prevalence setting. PLoS One. 2011; 6(5): e20077. 
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Thwaites GE, Chau TT, Caws M, et al.: Isoniazid resistance, mycobacterial 
genotype and outcome in Vietnamese adults with tuberculous meningitis. Int J 
Tuberc Lung Dis. 2002; 6(10): 865–71.  
PubMed Abstract 
7. Thwaites GE, Nguyen DB, Nguyen HD, et al.: Dexamethasone for the treatment 
of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004; 
351(17): 1741–51.  
PubMed Abstract | Publisher Full Text 
8. Török ME, Yen NT, Chau TT, et al.: Timing of initiation of antiretroviral therapy 
in human immunodeficiency virus (HIV)-associated tuberculous meningitis. 
Clin Infect Dis. 2011; 52(11): 1374–83.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Heemskerk AD, Bang ND, Mai NT, et al.: Intensified Antituberculosis Therapy in 
Adults with Tuberculous Meningitis. N Engl J Med. 2016; 374(2):  
124–34.  
PubMed Abstract | Publisher Full Text 
10. Alvarez-Uria G, Naik PK, Pakam R, et al.: Natural History and Factors 
Associated with Early and Delayed Mortality in HIV-Infected Patients Treated 
of Tuberculosis under Directly Observed Treatment Short-Course Strategy: A 
Prospective Cohort Study in India. Interdiscip Perspect Infect Dis. 2012; 2012: 
502012.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11. World Health Organization: Treatment of Tuberculosis: Guidelines. Fourth Edition. 
Geneva: World Health Organisation, 2010.  
PubMed Abstract 
12. Donald PR: Cerebrospinal fluid concentrations of antituberculosis agents in 
adults and children. Tuberculosis (Edinb). 2010; 90(5): 279–92.  
PubMed Abstract | Publisher Full Text 
13. Tho DQ, Török ME, Yen NT, et al.: Influence of antituberculosis drug resistance 
and Mycobacterium tuberculosis lineage on outcome in HIV-associated 
tuberculous meningitis. Antimicrob Agents Chemother. 2012; 56(6): 3074–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Thwaites GE, Lan NT, Dung NH, et al.: Effect of antituberculosis drug resistance 
on response to treatment and outcome in adults with tuberculous meningitis. 
J Infect Dis. 2005; 192(1): 79–88.  
PubMed Abstract | Publisher Full Text 
15. McIlleron H, Rustomjee R, Vahedi M, et al.: Reduced antituberculosis drug 
concentrations in HIV-infected patients who are men or have low weight: 
implications for international dosing guidelines. Antimicrob Agents Chemother. 
2012; 56(6): 3232–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Sahai J, Gallicano K, Swick L, et al.: Reduced plasma concentrations of 
antituberculosis drugs in patients with HIV infection. Ann Intern Med. 1997; 
127(4): 289–93.  
PubMed Abstract | Publisher Full Text 
17. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Decreased 
bioavailability of rifampin and other antituberculosis drugs in patients 
with advanced human immunodeficiency virus disease. Antimicrob Agents 
Chemother. 2004; 48(11): 4473–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Malabsorption of 
rifampin and isoniazid in HIV-infected patients with and without tuberculosis. 
Clin Infect Dis. 2004; 38(2): 280–3.  
PubMed Abstract | Publisher Full Text 
19. Patel KB, Belmonte R, Crowe HM: Drug malabsorption and resistant 
tuberculosis in HIV-infected patients. N Engl J Med. 1995; 332(5): 336–7. 
PubMed Abstract | Publisher Full Text 
20. Peloquin CA, MacPhee AA, Berning SE: Malabsorption of antimycobacterial 
medications. N Engl J Med. 1993; 329(15): 1122–3.  
PubMed Abstract | Publisher Full Text 
21. Berning SE, Huitt GA, Iseman MD, et al.: Malabsorption of antituberculosis 
medications by a patient with AIDS. N Engl J Med. 1992; 327(25): 1817–8. 
PubMed Abstract | Publisher Full Text 
22. Stott KE, Pertinez H, Sturkenboom MGG, et al.: Pharmacokinetics of rifampicin 
in adult TB patients and healthy volunteers: a systematic review and meta-
analysis. J Antimicrob Chemother. 2018.  
PubMed Abstract | Publisher Full Text 
23. Pasipanodya JG, McIlleron H, Burger A, et al.: Serum drug concentrations 
predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9): 
1464–73.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Ruslami R, Nijland HM, Alisjahbana B, et al.: Pharmacokinetics and tolerability 
of a higher rifampin dose versus the standard dose in pulmonary tuberculosis 
patients. Antimicrob Agents Chemother. 2007; 51(7): 2546–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25. Ruslami R, Ganiem AR, Dian S, et al.: Intensified regimen containing rifampicin 
and moxifloxacin for tuberculous meningitis: an open-label, randomised 
controlled phase 2 trial. Lancet Infect Dis. 2013; 13(1): 27–35.  
PubMed Abstract | Publisher Full Text 
26. Ellard GA, Humphries MJ, Allen BW: Cerebrospinal fluid drug concentrations 
and the treatment of tuberculous meningitis. Am Rev Respir Dis. 1993; 148(3): 
650–5.  
PubMed Abstract | Publisher Full Text 
27. van Ingen J, Aarnoutse RE, Donald PR, et al.: Why Do We Use 600 mg of 
Rifampicin in Tuberculosis Treatment? Clin infect Dis. 2011; 52(9): e194–9. 
PubMed Abstract | Publisher Full Text 
28. Boeree MJ, Heinrich N, Aarnoutse R, et al.: High-dose rifampicin, moxifloxacin, 
and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised 
controlled trial. Lancet Infect Dis. 2017; 17(1): 39–49.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Dian S, Yunivita V, Ganiem AR, et al.: High dose rifampicin for the treatment 
of TB meningitis: a dose finding study. 10th International Workshop on 
Pharmacology of TB Drugs,. Atlanta, USA; 2017.  
Reference Source
30. Heemskerk D, Day J, Chau TT, et al.: Intensified treatment with high dose 
rifampicin and levofloxacin compared to standard treatment for adult patients 
with tuberculous meningitis (TBM-IT): protocol for a randomized controlled 
trial. Trials. 2011; 12: 25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Meintjes G, Lawn SD, Scano F, et al.: Tuberculosis-associated immune 
reconstitution inflammatory syndrome: case definitions for use in resource-
limited settings. Lancet Infect Dis. 2008; 8(8): 516–23.  
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Health UMo: Consolidated Guidelines for the Prevention and Treatment of HIV 
in Ugdanda. Uganda: Ugandan Ministry of Health. 2016. 
Reference Source
33. Marais S, Thwaites G, Schoeman JF, et al.: Tuberculous meningitis: a uniform 
case definition for use in clinical research. Lancet Infect Dis. 2010; 10(11): 
803–12.  
PubMed Abstract | Publisher Full Text 
Page 14 of 20
Wellcome Open Research 2018, 3:83 Last updated: 06 SEP 2018
 Open Peer Review
  Current Referee Status:
Version 1
 28 August 2018Referee Report
doi:10.21956/wellcomeopenres.15997.r33459
 Mosepele Mosepele
University of Botswana & Botswana Harvard AIDS Institute Partnership (BHP), Gaborone, Botswana
Dr Cresswell and team are proposing an important, and long overdue Phase II trial, to test the optimal
Rifampicin dose for TBM in a population that suffers excess rates of TBM. Background literature is
comprehensive. Rationale for proposed work is clearly stated. Choice of study population is appropriate.
Many safety measure are in place.
Comments:
Main limitation is that the study sample size will allow descriptive comparison of the two investigational
arms, given the effort and resources dedicated to the conduct of the study.
Rationale for 20mg/kg IV versus 35mg/kg PO could be clarified, as in, data on comparability of these
doses should be included in the background section. The design implies that these are potentially
comparable.
Given that primary objective includes RIF drug levels, a possible ancillary study would be to collect and
store stool as alteration in gut microbial population has been known to affect drug metabolism in the
HIV-infected population. Future studies on banked stool samples may aide in additional understanding on
between subject differences in RIF levels.
Under clinical outcome, it would be important to include HIV RNA level (not just HIV disease) given
unknown interactions between high doses of RIF and DTG.
There is no data on interaction between high doses of RIF and Dolutegravir. Please comment on whether
patients on Dolutegravir will be included, and what safety measures will be taken. Please provide
preliminary information on pharmacokinetic data/rationale for assuming that 50mg DTG is sufficient in the
context of higher doses of RIF (20-35mg/kg) as compared to standard doses of RIF (10mg/kg).
Will ATT be given with pyridoxine in all 3 arms? If so, what dose(s)?
Will ATT be given with Cotrimoxazole in all 3 arms for active AIDS defining illness? If so, what dose(s)?
State rationale either way.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
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 Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 03 Sep 2018
, London School of Hygiene & Tropical Medicine, UKFiona Cresswell
 for We would like to sincerely thank Dr Mosepele for reviewing this protocol and providing
insightful and constructive comments.  In response to Dr Mosepele's comments:
1. Main limitation is that the study sample size will allow descriptive comparison of the two
investigational arms, given the effort and resources dedicated to the conduct of the study.
We absolutely agree the small sample size is a limitation in terms of detecting any clinical
benefit conferred by the intervention. The study is adequately powered for
pharmacokinetic endpoints, and we hope that this PK data will then serve as a foundation
 upon which to design a bigger phase III trial. 
2. Rationale for 20mg/kg IV versus 35mg/kg PO could be clarified, as in, data on comparability of
these doses should be included in the background section. The design implies that these are
potentially comparable.
 
Thank you for this great question. The oral dose of 35mg/kg was chosen based on it being
the highest dose for which there is adequate safety data in African adult TB patients, and
a dose/exposure at which a microbiological effect is seen (Boeree et al. Lancet ID 2017,
Svensson et al. Clinical Infectious Diseases 2018, Svensson et al. The Journal of
Infectious Diseases 2018). Moreover, the lower end of the total exposure range
approximates the AUC target value of 116 mg/L*h deduced in the analysis by Te
Brake et al., International Journal of Antimicrobial Agents 2015.
The intravenous dose was selected through discussion with Clinical Pharmacology
experts at Radboud University Medical Centre based upon their knowledge of the
dose-exposure relationship for intravenous and oral rifampicin gleaned from phase II
studies in TBM in Indonesia (Ruslami et al. Lancet ID 2013 and Yunivita et al. International
Journal of Antimicrobial Agents 2016 ). From these studies it appeared that oral 17-20
mg/kg was comparable with 13 mg/kg IV in terms of AUC . Correspondingly, an oral
dose increase of ~1.75 would result in an IV dose of little over 20 mg/kg. Although the
reviewer is right that it would seem that this line of reasoning implies that the oral and IV
arm are comparable, this is actually not the case. In the study by Yunivita et al., which
directly compares oral vs IV dosing, it was shown that oral C  values did not reach
0-24h 
0-24h
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 directly compares oral vs IV dosing, it was shown that oral C  values did not reach
those achieved after IV dosing. Such a high initial peak exposure may be hypothetically
relevant for e.g. improved blood-brain-barrier penetration, and saturation of plasma
proteins with higher free rifampicin concentrations as a result. The proposed study may
provide further insights into these hypotheses. 
3. Given that primary objective includes RIF drug levels, a possible ancillary study would be to
collect and store stool as alteration in gut microbial population has been known to affect drug
metabolism in the HIV-infected population. Future studies on banked stool samples may aide in
additional understanding on between subject differences in RIF levels.
 
Thank you for this idea, we will certainly discuss it as a team.  
4. Under clinical outcome, it would be important to include HIV RNA level (not just HIV disease)
given unknown interactions between high doses of RIF and DTG.
There is no data on interaction between high doses of RIF and Dolutegravir. Please comment
on whether patients on Dolutegravir will be included, and what safety measures will be taken.
Please provide preliminary information on pharmacokinetic data/rationale for assuming that 50mg
DTG is sufficient in the context of higher doses of RIF (20-35mg/kg) as compared to standard
doses of RIF (10mg/kg).
 
In Uganda, DTG is only at the very early stages of roll-out as an alternative first line
option. Hence the majority of our participants will be either:
a) ART naïve
b) failing or stable on EFV (PI-based regimens are excluded) 
c) a small proportion may present with unmasking TB having recently initiated ART (either
DTG or EFV-based, PIs excluded) 
I will deal with each scenario individually: 
a) ART naïve - commence ART at week 8 by which time the intervention (high dose RIF)
will have finished, so they could receive either DTG 50mg twice daily for the remainder of
continuation phase of TB treatment or an EFV-based regimen. The INSPIRING study
(NCT02178592) presented at CROI 2018 showed that DTG 50 mg twice daily appeared to
be effective and well-tolerated in HIV/TB co-infected adults receiving standard dose
RIF-based TB therapy. 
 
b) failing or stable on EFV – we would aim to switch those who are failing EFV to a second
line regimen at week 8. The intervention has finished at this point and participants are on
standard dose continuation phase ATT. Due to the interaction between PIs and RIF we
would opt for DTG 50mg twice daily, see rationale above. 
 
c) unmasking TB having recently initiated ART (either DTG or EFV-based) - RIFAVIRENZ
trial investigated co-administration of high dose rifampicin 20mg/kg with efavirenz 600mg
and 800mg - following EFV 600mg the plasma concentrations were similar with standard
dose rifampicin (10mg/kg) and high dose rifampicin (20mg/kg). So, EFV would be
continued at 600mg od. 
For any participants on DTG we would dose-adjust the DTG to 50mg twice daily. Data on
high-dose rifampicin and DTG co-administration are awaited. However, it is generally
believed that the degree of rifampicin-mediated enzyme induction is not a dose-related
max
Page 17 of 20
Wellcome Open Research 2018, 3:83 Last updated: 06 SEP 2018
 believed that the degree of rifampicin-mediated enzyme induction is not a dose-related
)phenomenon (Niemi et al. Clinical Pharmacokinetics 2003 . This would fit with data from
RIFAVIRENZ. 
 
However, you make an excellent point that the virological response of participants must
be carefully monitored and we will ensure to stay abreast of any new information arising
on this topic. 
5. Will ATT be given with pyridoxine in all 3 arms? If so, what dose(s)?
 
Good point. In Uganda it is standard of care to take pyridoxine 25mg od whilst on ATT to
prevent isoniazid-related peripheral neuropathy so all participants will receive pyridoxine. 
6. Will ATT be given with Cotrimoxazole in all 3 arms for active AIDS defining illness? If so, what
dose(s)? State rationale either way.
 
Co-trimoxazole prophylaxis 960mg once daily is given to all HIV-positive adults regardless
of CD4 count as standard of care in Uganda. We will abide by these national guidelines in
 all arms.
 No competing interests were disclosed.Competing Interests:
 23 July 2018Referee Report
doi:10.21956/wellcomeopenres.15997.r33458
   Joseph Donovan
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
Dr Cresswell  present their study protocol for a phase II open label, randomised controlled trial of highet al 
dose oral and intravenous rifampicin therapy in a predominantly HIV co-infected population with TBM.
The study will allocate patients to one of 3 strategies; intravenous 20mg/kg/day rifampicin for 2-weeks
followed by oral rifampicin 35mg/kg/day for 6-weeks, oral 35mg/kg/day rifampicin for 8-weeks, or
standard of care oral rifampicin (10mg/kg/day) for 8-weeks. Primary outcomes will be pharmacokinetic
parameters in plasma and CSF, and safety.  
This study aims to provide data on an important research topic; namely the optimum dosing of rifampicin
in TBM given the drugs poor penetration into CSF. An HIV co-infected population is unique given their
worse outcomes, altered anti-tuberculous drug absorption, and the complex drug interactions that occur
due to both cytochrome P450 enzyme induction and inhibition with the various drugs used to treat TB and
HIV. 
This protocol is well written, and the design well thought through. The introduction has a logical flow and
presents the problem and the available evidence up to this point. Important sub studies will assess
GeneXpert Ultra as a diagnostic tool in TBM, and interestingly brain tissue rifampicin concentrations on
autopsy specimens, given the importance of rifampicin’s brain tissue penetration as well as its CSF
penetration. 
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 The study hypotheses and objectives are clearly described, and the methods reproducible. Identifying
any safety issues is clearly important, and the data collection timepoints appear logical. Drug induced liver
injury (DILI) will be monitored for and ‘participants will be replaced a posteriori if baseline ALT>3x ULN’.
Safety analysis will include an analysis of the occurrence of DILI. Efavirenz or dose-adjusted dolutegravir
regimens will be used, and patients receiving protease inhibitor or nevirapine-based ART will be
excluded, due to their unsuitability with concomitant rifampicin. Study patients requiring changes to
pre-established ART during the intervention period (where rifampicin-safe ART becomes unsuitable for
any reason) will present a challenge to the team if alternative options become limited, and protease
inhibitors must be considered. 
The authors plan an interim safety analysis after 24 participants (8 per arm) have completed their week 8
visit, to allow modification of the frequency of interim analysis and early study termination if deemed
necessary. Given only 60 patients will enrol (20 to each arm), and the mortality in this patient group is
expected to be high (many enrolled patients may not survive to their 8-week visit), the authors may find
they need to perform this interim analysis sooner, or else perform it when 24 patients (8 in each arm) have
been enrolled, and the most recent patient has reached their 8-week follow up or would have reached
8-weeks if they were still alive. Otherwise at the point of the safety analysis the authors may find that too
many patients have already been enrolled to make a meaningful change to the study, if indeed any
change is required.   
In summary, this is a clear and well written protocol that addresses an important research question. 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
 No competing interests were disclosed.Competing Interests:
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 03 Sep 2018
, London School of Hygiene & Tropical Medicine, UKFiona Cresswell
Thank you Dr Donovan for your carefully considered review and summary of the trial. Dr
Donovan makes an excellent point about the complexity of managing TB/HIV co-infection
in ART experienced patients, which is compounded by intermittent availability of rifabutin.
Thank you for your comments about optimal timing of the interim safety analysis – an
excellent suggestion. As the study is open-label we can keep a close eye on accumulating
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 excellent suggestion. As the study is open-label we can keep a close eye on accumulating
safety data as patients enrol and will expedite the interim analysis if there are any
 concerns. 
 No competing interests were disclosed.Competing Interests:
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